Novartis considers sale of generics drug business: Bloomberg

Novartis AG is considering a sale of its dermatology generics drugs business and the unit could be valued at between $1 billion to $1.5 billion, Bloomberg said. The assets for sale include skin-care treatments and some manufacturing facilities, the story said. Private equity and other drug makers are expected to be interested, the report said.